Skip to main content
Back to News
Enveda raises $311 million to advance AI-discovered natural-molecule drugs
Funding
2 min read
US

Enveda raises $311 million to advance AI-discovered natural-molecule drugs

The AMW Read

The round confirms an already reported financing event, while the size of the raise and the clinical-stage pipeline make its outcome meaningful for AI-driven drug discovery.
NoveltySignificance
Healthcare & Bio · Player Map
Enveda
Enveda

AI in Biotech / Drug Discovery

View Company Profile

Enveda raises $311 million to advance AI-discovered natural-molecule drugs

Enveda raised $311 million in a Series E led by Catalio Capital Management, bringing its cumulative funding above $845 million. New investors include ICONIQ, Lightspeed, Durable Capital Partners and an unnamed sovereign wealth fund. The US biotech uses its PRISM platform to analyze mass-spectrometry data from natural samples, infer molecular structures and guide experiments that assess potential drug candidates. Chemists then optimize selected molecules for oral use.

The financing backs a drug-discovery approach built around identifying compounds that already exist in nature, rather than designing every candidate from scratch. Enveda says PRISM turns complex sample data into a ranked set of molecules for laboratory work. Its pipeline has reached human testing: ENV-294 has begun Phase 2 trials for atopic dermatitis and asthma, while ENV-308 and the inflammatory bowel disease candidate ENV-6946 have entered Phase 1 studies. That progression matters for AI-driven biotech because a platform's ability to find candidates is only one step toward establishing whether those candidates work in patients.

For investors, the next evidence to watch is clinical data, particularly from ENV-294's two Phase 2 indications. Those results can test the connection between Enveda's discovery process and therapeutic outcomes more directly than the size of this round can. For builders pursuing AI-assisted drug discovery, Enveda's workflow also shows where software meets laboratory execution: mass-spectrometry interpretation helps prioritize molecules, but experiments, chemical optimization and clinical trials still determine which candidates can advance.

#Enveda #AIDrugDiscovery #Biotech #NaturalProducts #VentureFunding

#Enveda#Series E#AI drug discovery#natural molecules#related:Catalio

How This Connects

Based on Healthcare & Bio · Player Map

  1. 4d agoIsomorphic Labs raises $5 billion Series C for AI drug discoveryIsomorphic Labs
  2. 0mo agoPathos AI raises $237M to scale Foundry and advance four oncology assetsPathos
  3. 1mo agoWarp Sciences, founded by former OpenAI science lead Kevin Weil, raises $215M to automate drug-chemistry labsWarp Sciences
  4. 1mo agoEnveda raises $311 million to advance AI-discovered natural-molecule drugs · THIS ARTICLE

More news from Enveda

Stay updated with the latest news and announcements from Enveda.

View all Enveda news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard